Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients
Status:
Withdrawn
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the overall response rate of Genexol-PM compared
with paclitaxel (cremophor-based paclitaxel) as palliative chemotherapy in
anthracycline-pretreated patients with metastatic breast cancer.